Companies wanting to keep sensitive research data on-site are discovering a major infrastructure challenge. Even a small, local data center can double a lab facility's total power consumption, a critical and costly factor that must be planned for well in advance of securing space.
While automation is crucial for ensuring consistent, replicable experiments by eliminating human variability, it risks removing the "irregularity" that can lead to unexpected breakthroughs. This creates a new design challenge: engineering for human ingenuity alongside automated systems.
Traditional "flexible" lab design pre-engineers for every possible future scenario, which is expensive and rigid. A smarter approach is "adaptability": consciously designing pathways and leaving space for future technology without over-investing in systems that may quickly become obsolete.
The deep focus required by computational scientists clashes with the open-office model. Furthermore, the emerging behavior of researchers verbally interacting with AI models introduces new acoustic and privacy challenges, making traditional layouts unsuitable for the focused nature of modern R&D.
As AI and automation become central to drug discovery, the physical layout and infrastructure of a lab are no longer just a facility. They are a core competitive advantage, an "experiment upon themselves" that companies actively protect as valuable IP to prevent replication by rivals.